Bausch Health Companies Inc. (NYSE:BHC) is Biglari Capital CORP.'s 8th Largest Position

Biglari Capital CORP. reduced its position in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 25.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 295,000 shares of the company's stock after selling 100,000 shares during the period. Bausch Health Companies comprises approximately 0.3% of Biglari Capital CORP.'s holdings, making the stock its 8th largest holding. Biglari Capital CORP. owned about 0.08% of Bausch Health Companies worth $2,378,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Mountain Hill Investment Partners Corp. bought a new position in Bausch Health Companies during the 4th quarter worth $56,000. Bank of Nova Scotia bought a new stake in Bausch Health Companies in the 4th quarter valued at about $83,000. One68 Global Capital LLC acquired a new position in Bausch Health Companies during the 4th quarter valued at about $90,000. Alpine Global Management LLC bought a new position in Bausch Health Companies in the 4th quarter worth about $114,000. Finally, Tobam increased its stake in shares of Bausch Health Companies by 10.4% in the fourth quarter. Tobam now owns 15,034 shares of the company's stock valued at $121,000 after purchasing an additional 1,422 shares during the period. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Companies Price Performance

Shares of Bausch Health Companies stock traded down $0.04 during trading on Wednesday, hitting $4.71. The stock had a trading volume of 2,901,192 shares, compared to its average volume of 2,671,570. The business has a fifty day moving average of $5.89 and a two-hundred day moving average of $7.15. The firm has a market cap of $1.74 billion, a P/E ratio of -39.21, a PEG ratio of 0.37 and a beta of 0.34. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $9.85.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The business had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. As a group, research analysts forecast that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BHC. Royal Bank of Canada increased their price objective on Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a report on Friday, May 2nd. Jefferies Financial Group reissued a "hold" rating and issued a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Finally, StockNews.com upgraded shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.